Analysts expect TG Therapeutics, Inc. (NASDAQ:TGTX) to report $-0.46 EPS on March, 9.They anticipate $0.02 EPS change or 4.17% from last quarter’s $-0.48 EPS. After having $-0.48 EPS previously, TG Therapeutics, Inc.’s analysts see -4.17% EPS growth. The stock decreased 3.56% or $0.45 during the last trading session, reaching $12.2. About 1.19 million shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 60.54% since February 19, 2017 and is uptrending. It has outperformed by 43.84% the S&P500.
EnPro Industries, Inc. designs, develops, makes, and markets engineered industrial products worldwide. The company has market cap of $1.65 billion. The companyÂ’s Sealing Products segment offers metallic, non-metallic, and composite material gaskets; dynamic seals; compression packings; resilient metal seals; elastomeric seals; hydraulic components; expansion joints; flange sealing and isolation products; pipeline casing spacers/isolators; casing end seals; modular sealing systems for sealing pipeline penetrations; hole forming products; manhole infiltration sealing systems; heavy-duty truck wheel-end component systems; bellows and bellows assemblies; pedestals for semiconductor manufacturing; and polytetrafluoroethylene products. It has a 3.18 P/E ratio. This segmentÂ’s products are used in the chemical and petrochemical processing, petroleum extraction and refining, pulp and paper processing, power generation, food and pharmaceutical processing, primary metal manufacturing, mining, water and waste treatment, heavy-duty trucking, aerospace, medical, filtration, and semiconductor fabrication industries.
Investors sentiment decreased to 1.21 in 2017 Q3. Its down 1.07, from 2.28 in 2017Q2. It fall, as 11 investors sold TG Therapeutics, Inc. shares while 22 reduced holdings. 11 funds opened positions while 29 raised stakes. 35.13 million shares or 3.60% more from 33.91 million shares in 2017Q2 were reported. Kennedy Cap Mgmt invested in 0.09% or 421,229 shares. Schwab Charles Invest Mgmt has 243,485 shares. Alliancebernstein Limited Partnership holds 0% or 59,940 shares in its portfolio. Northern Corporation holds 596,898 shares. Credit Suisse Ag holds 224,066 shares or 0% of its portfolio. Dupont Capital Management Corporation holds 25,662 shares. Metropolitan Life Ins Co Ny accumulated 30,247 shares. Jpmorgan Chase Com has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Eam Invsts Ltd Co stated it has 308,120 shares. Segall Bryant & Hamill Limited Liability Corporation accumulated 0.01% or 53,592 shares. Manufacturers Life Insur The accumulated 0% or 36,397 shares. Moreover, Sei Investments Communication has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 44 shares. 3,056 were reported by Victory Capital Mngmt. Tiaa Cref Management Limited Liability holds 0% or 122,638 shares in its portfolio. Bessemer Gru reported 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX).
Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 19 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given on Tuesday, November 14 by H.C. Wainwright. FBR Capital maintained TG Therapeutics, Inc. (NASDAQ:TGTX) on Friday, February 2 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Monday, December 11. The rating was reinitiated by Brean Capital with “Buy” on Thursday, October 6. The firm has “Buy” rating given on Friday, May 27 by Suntrust Robinson. As per Wednesday, August 12, the company rating was upgraded by Zacks. On Friday, May 27 the stock rating was initiated by SunTrust with “Buy”. The firm has “Strong Buy” rating by Raymond James given on Wednesday, September 9. H.C. Wainwright maintained TG Therapeutics, Inc. (NASDAQ:TGTX) rating on Tuesday, March 7. H.C. Wainwright has “Buy” rating and $18 target. The rating was maintained by B. Riley & Co on Friday, December 1 with “Buy”.
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $861.96 million. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.
Since December 29, 2017, it had 0 insider purchases, and 1 sale for $272,051 activity. Shares for $272,051 were sold by Power Sean A on Friday, December 29.
Analysts await EnPro Industries, Inc. (NYSE:NPO) to report earnings on February, 21. They expect $0.65 EPS, up 333.33% or $0.50 from last year’s $0.15 per share. NPO’s profit will be $13.86M for 29.66 P/E if the $0.65 EPS becomes a reality. After $0.73 actual EPS reported by EnPro Industries, Inc. for the previous quarter, Wall Street now forecasts -10.96% negative EPS growth.
Silver Point Capital L.P. holds 9.8% of its portfolio in EnPro Industries, Inc. for 1.90 million shares. Daruma Capital Management Llc owns 753,723 shares or 3.78% of their US portfolio. Moreover, Skyline Asset Management Lp has 2.12% invested in the company for 332,200 shares. The Illinois-based Advisory Research Inc has invested 0.66% in the stock. Eam Investors Llc, a California-based fund reported 37,129 shares.
The stock increased 0.94% or $0.72 during the last trading session, reaching $77.12. About 185,901 shares traded or 28.75% up from the average. EnPro Industries, Inc. (NPO) has risen 42.29% since February 19, 2017 and is uptrending. It has outperformed by 25.59% the S&P500.